NASDAQ:PYXS Pyxis Oncology (PYXS) Stock Price, News & Analysis → ‘America’s Top Trader’ Who Predicted the Biggest Financial Events of The Last 30 Years, Issues New Warning… (From InvestorPlace) (Ad) Free PYXS Stock Alerts $3.74 +0.02 (+0.54%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$3.71▼$3.8750-Day Range$3.65▼$5.5852-Week Range$1.35▼$6.85Volume246,178 shsAverage Volume689,716 shsMarket Capitalization$220.25 millionP/E RatioN/ADividend YieldN/APrice Target$8.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Pyxis Oncology alerts: Email Address Pyxis Oncology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside135.3% Upside$8.80 Price TargetShort InterestHealthy4.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.15Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.09) to ($1.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.56 out of 5 starsMedical Sector737th out of 929 stocksPharmaceutical Preparations Industry345th out of 438 stocks 3.5 Analyst's Opinion Consensus RatingPyxis Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePyxis Oncology has only been the subject of 3 research reports in the past 90 days.Read more about Pyxis Oncology's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.16% of the float of Pyxis Oncology has been sold short.Short Interest Ratio / Days to CoverPyxis Oncology has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pyxis Oncology has recently increased by 5.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPyxis Oncology does not currently pay a dividend.Dividend GrowthPyxis Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PYXS. Previous Next 3.4 News and Social Media Coverage News SentimentPyxis Oncology has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Pyxis Oncology this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for PYXS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows8 people have added Pyxis Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pyxis Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.30% of the stock of Pyxis Oncology is held by insiders.Percentage Held by InstitutionsOnly 39.09% of the stock of Pyxis Oncology is held by institutions.Read more about Pyxis Oncology's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pyxis Oncology are expected to decrease in the coming year, from ($1.09) to ($1.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pyxis Oncology is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pyxis Oncology is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPyxis Oncology has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pyxis Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 Media[Urgent!] Generational Wealth GameplanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Pyxis Oncology Stock (NASDAQ:PYXS)Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Read More PYXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PYXS Stock News HeadlinesMay 30 at 7:30 AM | globenewswire.comPyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceMay 27, 2024 | americanbankingnews.comPyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Buy" by AnalystsMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Strong Financials and Promising Clinical ProgressMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Robust Clinical Pipeline and Solid FinancialsMay 14, 2024 | globenewswire.comPyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024May 9, 2024 | globenewswire.comPyxis Oncology to Present at the RBC Capital Markets Global Healthcare ConferenceApril 14, 2024 | finance.yahoo.comPYXS Oct 2024 10.000 callApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology as PYX-201 Showcases Promising Preclinical Data and Broad Therapeutic PotentialApril 3, 2024 | msn.comWhy Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionMarch 28, 2024 | globenewswire.comPyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aura Biosciences Inc (AURA), Spectral AI (MDAI) and Pyxis Oncology (PYXS)March 28, 2024 | seekingalpha.comPyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The WaitMarch 27, 2024 | investorplace.com3 Biotech Stocks to Buy on the Dip: March 2024March 27, 2024 | msn.comPyxis Oncology gets $8M payment for sale pf royalty rightsMarch 27, 2024 | globenewswire.comPyxis Oncology Obtains $8 Million Payment for the Sale of Royalty RightsMarch 25, 2024 | markets.businessinsider.comOptimistic Buy Rating for Pyxis Oncology’s PYX-201 Based on Strong Safety Profile and Promising Therapeutic PotentialMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pyxis Oncology on Strong Clinical and Financial ProspectsMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed: Pyxis Oncology’s Financial Health and Promising Drug Candidate PYX-201 Bolster OptimismMarch 21, 2024 | marketwatch.comPyxis Oncology Shares Fall 10% After Apparent Delay in ResultsMarch 21, 2024 | investorplace.comPYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023March 21, 2024 | benzinga.comPyxis Oncology: Q4 Earnings InsightsMarch 21, 2024 | finance.yahoo.comPyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial ChallengesMarch 21, 2024 | globenewswire.comPyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023March 19, 2024 | investorplace.comFrom Six Figures to Seven: 3 Biotech Stocks Set to Make MillionairesMarch 19, 2024 | markets.businessinsider.comPyxis Oncology (PYXS) Receives a Buy from Leerink PartnersSee More Headlines Receive PYXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pyxis Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2024Today5/31/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PYXS CUSIPN/A CIK1782223 Webwww.pyxisoncology.com Phone617-221-9059FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$8.80 High Stock Price Target$12.00 Low Stock Price Target$7.00 Potential Upside/Downside+128.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,790,000.00 Net MarginsN/A Pretax Margin-358.00% Return on Equity-38.99% Return on Assets-30.59% Debt Debt-to-Equity RatioN/A Current Ratio12.19 Quick Ratio12.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.13 per share Price / Book1.23Miscellaneous Outstanding Shares58,890,000Free Float53,411,000Market Cap$227.32 million OptionableOptionable Beta1.45 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Lara S. Sullivan M.D.MBA, CEO, President & DirectorMs. Pamela Yanchik Connealy M.B.A. (Age 62)CFO & COO Comp: $709.7kDr. Ken Kobayashi FACP (Age 63)M.D., Chief Medical Officer Comp: $314.08kMr. Jitendra Wadhane (Age 43)Chief Accounting Officer, Senior VP of Finance & Corporate Controller Dr. Balu N. Balasubramanian Ph.D.Interim Chief Technology OfficerDr. Jan Pinkas Ph.D.Chief Scientific OfficerDr. Charles T. Gombar Ph.D.Senior Vice President of Portfolio & Program ManagementMore ExecutivesKey CompetitorsRani TherapeuticsNASDAQ:RANIMacroGenicsNASDAQ:MGNXADC TherapeuticsNYSE:ADCTAdicet BioNASDAQ:ACETShattuck LabsNASDAQ:STTKView All CompetitorsInsiders & InstitutionsCetera Advisors LLCBought 23,500 shares on 5/24/2024Ownership: 0.040%Ikarian Capital LLCBought 1,662,408 shares on 5/17/2024Ownership: 2.823%StemPoint Capital LPBought 1,794,195 shares on 5/14/2024Ownership: 3.047%Vanguard Group Inc.Bought 94,740 shares on 5/10/2024Ownership: 2.380%SG Americas Securities LLCBought 13,809 shares on 5/7/2024Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions PYXS Stock Analysis - Frequently Asked Questions Should I buy or sell Pyxis Oncology stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pyxis Oncology in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PYXS shares. View PYXS analyst ratings or view top-rated stocks. What is Pyxis Oncology's stock price target for 2024? 7 Wall Street analysts have issued twelve-month price objectives for Pyxis Oncology's stock. Their PYXS share price targets range from $7.00 to $12.00. On average, they expect the company's share price to reach $8.80 in the next twelve months. This suggests a possible upside of 135.3% from the stock's current price. View analysts price targets for PYXS or view top-rated stocks among Wall Street analysts. How have PYXS shares performed in 2024? Pyxis Oncology's stock was trading at $1.80 on January 1st, 2024. Since then, PYXS shares have increased by 107.8% and is now trading at $3.74. View the best growth stocks for 2024 here. When is Pyxis Oncology's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our PYXS earnings forecast. How were Pyxis Oncology's earnings last quarter? Pyxis Oncology, Inc. (NASDAQ:PYXS) issued its earnings results on Saturday, May, 11th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.19. The business earned $16.15 million during the quarter, compared to analysts' expectations of $4.25 million. What ETF holds Pyxis Oncology's stock? Tema Oncology ETF holds 16,476 shares of PYXS stock, representing 0.34% of its portfolio. When did Pyxis Oncology IPO? Pyxis Oncology (PYXS) raised $158 million in an initial public offering on Friday, October 8th 2021. The company issued 10,500,000 shares at $14.00-$16.00 per share. Who are Pyxis Oncology's major shareholders? Pyxis Oncology's stock is owned by many different retail and institutional investors. Top institutional shareholders include StemPoint Capital LP (3.05%), Ikarian Capital LLC (2.82%), Vanguard Group Inc. (2.38%), Susquehanna Fundamental Investments LLC (0.14%), Cetera Advisors LLC (0.04%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Darren S Cline, Jitendra Wadhane, Lara Sullivan, Mark Chin, Pamela Ann Connealy, Pfizer Inc and Thomas Civik. View institutional ownership trends. How do I buy shares of Pyxis Oncology? Shares of PYXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PYXS) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyOn June 10, Nvidia makes its next big moveWeiss RatingsMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryUnlock Explosive Gains with This Defense StockBehind the MarketsElon’s Revenge on BidenTradeSmithClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
